215 related articles for article (PubMed ID: 37188777)
41. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
[TBL] [Abstract][Full Text] [Related]
42. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
43. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
44. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
46. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract][Full Text] [Related]
48. Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality.
Liu J; Han W; Cai X; Wang Z; Cao L; Hua H; Jia Z; Chao H; Lu X; Shen H
Hematology; 2022 Dec; 27(1):565-574. PubMed ID: 35549661
[TBL] [Abstract][Full Text] [Related]
49. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
50. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia.
Abd El-Lateef AE; Ismail MM; Almohammadi M; Gawaly AM
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):92-98. PubMed ID: 34933728
[TBL] [Abstract][Full Text] [Related]
51. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.
Schnittger S; Dicker F; Kern W; Wendland N; Sundermann J; Alpermann T; Haferlach C; Haferlach T
Blood; 2011 Feb; 117(8):2348-57. PubMed ID: 21148331
[TBL] [Abstract][Full Text] [Related]
52. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
53. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
54. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia.
Xu LH; Fang JP; Liu YC; Jones AI; Chai L
Blood Cancer J; 2020 Jan; 10(1):1. PubMed ID: 31915364
[TBL] [Abstract][Full Text] [Related]
55. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Nachmias B; Krichevsky S; Filon D; Even-Or E; Gatt ME; Saban R; Avni B; Grisariu S; Aumann S; Vainstein V
Acta Haematol; 2022; 145(6):642-649. PubMed ID: 35933982
[TBL] [Abstract][Full Text] [Related]
56. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
Waidhauser J; Labopin M; Esteve J; Kröger N; Cornelissen J; Gedde-Dahl T; Van Gorkom G; Finke J; Rovira M; Schaap N; Petersen E; Beelen D; Bunjes D; Savani B; Schmid C; Nagler A; Mohty M;
Bone Marrow Transplant; 2021 Oct; 56(10):2445-2453. PubMed ID: 34059800
[TBL] [Abstract][Full Text] [Related]
58. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Venugopal S; DiNardo CD; Loghavi S; Qiao W; Ravandi F; Konopleva M; Kadia T; Bhalla K; Jabbour E; Issa GC; Macaron W; Daver N; Borthakur G; Montalban-Bravo G; Yilmaz M; Patel KP; Kanagal-Shamanna R; Chien K; Maiti A; Kantarjian H; Short NJ
Am J Hematol; 2022 Dec; 97(12):1560-1567. PubMed ID: 36087091
[TBL] [Abstract][Full Text] [Related]
59. [Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations].
Chen SF; Wang TZ; Jiang SH; Shen HJ; Xu Y; Zhou HF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):983-988. PubMed ID: 30612398
[No Abstract] [Full Text] [Related]
60. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
